Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial disclosures and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition and Integration - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., aiming to double its total addressable market and enhance sales [2][3]. - The integration of Pro-ficiency has reportedly faced challenges, contradicting the company's earlier claims of effective integration and internal controls [3]. Financial Performance and Stock Impact - On June 11, 2025, Simulations Plus announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 results, which further impacted stock performance, causing a nearly 26% decline in share price [5]. Auditor Dismissal and Findings - Following the disappointing results, Simulations Plus dismissed its auditor, Grant Thornton LLP, which raised concerns about segment reporting and internal controls [5]. - Grant Thornton indicated unresolved issues regarding the company's financial reporting and internal controls, which contributed to the stock's decline [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Insights - The article highlights the investment strategies and achievements of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and algorithmic analysis for identifying investment opportunities [1] Group 1: Investment Strategies - Paul Franke developed a system called "Victory Formation," which focuses on supply/demand imbalances indicated by specific stock price and volume movements [1] - The "Bottom Fishing Club" articles target deep value stocks or those showing significant upward technical momentum reversals [1] - "Volume Breakout Report" articles analyze positive trend changes supported by strong price and volume trading actions [1] Group 2: Performance and Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and achieved the 1 position in the Motley Fool® CAPS stock picking contest in 2008 and 2009, out of over 60,000 portfolios [1] - As of September 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance over the last decade [1] Group 3: Risk Management - Franke advises investors to implement stop-loss levels of 10% or 20% on individual stock choices and to maintain a diversified portfolio of at least 50 well-positioned stocks to enhance regular stock market outperformance [1]

Core Viewpoint - Hagens Berman has initiated an investigation into Simulations Plus, Inc. following a significant stock price drop of approximately 25% due to alarming disclosures, including a large asset impairment charge and the termination of its independent auditor, Grant Thornton [1][3]. Financial Performance - Simulations Plus reported a net loss of $67.3 million for Q3 2025, primarily driven by a $77.2 million impairment charge related to prior acquisitions, aimed at aligning asset book values with current market values [3]. Auditor Termination - The company terminated its engagement with Grant Thornton, which had been hired just two months prior, citing the auditor's inability to finalize matters related to segment reporting and internal controls in time for the quarterly report [3]. - Grant Thornton contradicted Simulations Plus's explanation in a letter to the SEC, stating that it had raised specific concerns regarding segment reporting and internal controls that were not resolved satisfactorily at the time of termination [4]. Investigation Focus - Hagens Berman's investigation is centered on whether Simulations Plus misled investors regarding the reasons for the auditor's dismissal and whether its financial statements accurately reflected asset values [5]. - The firm is examining the discrepancies between Simulations Plus's public statements and the auditor's communications to the SEC, highlighting the potential implications for investor trust [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Simulations Plus, Inc. regarding possible violations of federal securities laws, particularly related to alleged misrepresentations and omissions by the company and its executives [1] Company Background - Simulations Plus is a software company that serves the pharmaceutical, biotechnology, and chemical industries [3] - In June 2024, the company acquired Pro-ficiency Holdings, Inc., claiming this acquisition would double its total addressable market and serve as a key driver of growth [3] Recent Developments - On June 11, 2025, Simulations Plus announced disappointing preliminary results for Q3 2025, attributing the downturn to "market uncertainties," which led to a stock price drop of over 24%, from $26.44 to $20.05 per share [4] - Following this, on July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed its auditor, Grant Thornton LLP, which raised concerns about unresolved issues with segment reporting and internal controls [4] - The dismissal of the auditor and the acknowledgment of unresolved issues caused the stock to fall nearly 26%, from $17.47 to $12.97 per share [4]

Company Overview - Simulations Plus is celebrating its 30th anniversary, indicating a long-standing presence in the biosimulation market [2] - The company specializes in biosimulation, which supports drug development through the integration of technology, science, mathematics, and various biological disciplines [3] Product and Services - The platform offers a comprehensive range of solutions that cover the entire drug development process, from early-stage discovery to clinical studies and post-approval applications [4] - Biosimulation is utilized to enhance efficiency and accelerate timelines in drug development, including applications in animal testing and clinical trials [4][5] Industry Context - The acceptance of biosimulation has grown over the years, gaining recognition from both scientific communities and drug sponsors [5]

Core Insights - Simulations Plus is celebrating its 30th anniversary, indicating its established presence in the biosimulation market [2] - The company utilizes a combination of technology, science, mathematics, and various disciplines to develop in silico models that enhance drug development efficiency [3] Company Overview - Simulations Plus offers a comprehensive platform that supports various stages of drug development, from early discovery to clinical studies and post-approval applications [4] - The platform includes applications for lead optimization, preclinical translational impact, and modeling that supports bioequivalence waivers [4] Industry Context - Biosimulation has gained acceptance over the years from scientific and drug sponsor perspectives, highlighting its importance in the drug development process [5]

Summary of Simulation Plus Conference Call Company Overview - Simulation Plus is celebrating its 30th anniversary, indicating a long-standing presence in the bio simulation market [2] - The company specializes in software licensing and scientific consulting services to support drug development [4] Industry Insights - Bio simulation combines technology, science, and regulatory support to enhance drug development efficiency [3] - The FDA has shown increasing support for bio simulation, particularly in reducing animal testing requirements [3][22] Core Business and Services - The company provides tools for various stages of drug development, including discovery, preclinical, and clinical phases [5][6] - Key products include: - **Admet Predictor**: Focused on early-stage applications, representing 15% of client support [6][7] - **GastroPlus**: A PBPK modeling tool used extensively in translational medicine and clinical trial design [7][8] - **PKPD Modeling**: Used for profiling drugs and patient stratification, crucial for personalized medicine [8] AI and Drug Development - AI has been integrated into the company's products for decades, enhancing data analysis and candidate identification [9][10] - The use of AI is seen as a revolutionary tool in drug development, improving efficiency and success rates [10][12] - Challenges include ensuring data quality and managing large datasets effectively [11][13] Regulatory Environment - The FDA's roadmap to reduce animal testing presents opportunities for Simulation Plus, as biosimulation can potentially replace some traditional methods [22][23] - The adoption of biosimulation is expected to grow, but the process will take time due to regulatory scrutiny [24][25] Market Challenges - The biopharma and biotech sectors are currently facing a challenging demand environment, with cost constraints and low funding impacting client investments [31][32] - Despite these challenges, there is a strong need for improved ROI in drug development, which bio simulation can address [33][34] Strategic Realignment - The company has undergone a reorganization to create a more functional organization, enhancing collaboration across different scientific domains [35][36] - The integration of products and development of cloud technology aims to accelerate the company's roadmap and improve client offerings [37] Future Opportunities - The company is focused on staying current with advancements in science and regulatory guidance, particularly in oncology and other therapeutic areas [39][41] - There is a long runway for biosimulation value in drug development, with ongoing opportunities for innovation and market solutions [41][42]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings and subsequent financial reporting challenges [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings in June 2024, aiming to enhance its market reach and sales [2]. Group 2: Financial Reporting Issues - Simulations Plus claimed that the integration of Pro-ficiency would double its total addressable market and significantly boost sales, but it appears the integration was not successful and internal controls were ineffective [3]. - The company reported disappointing preliminary financial results for Q3 2025, citing market uncertainties, which led to a significant stock price drop of over 24% from $26.44 to $20.05 per share [4]. - A $77.2 million charge related to prior acquisitions was reported in Q3 2025, alongside the dismissal of its auditor Grant Thornton, which raised concerns about the company's internal controls and segment reporting [5]. Group 3: Stock Performance - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26%, from $17.47 to $12.97 per share [5].